BioCardia (NASDAQ:BCDA – Get Free Report) and Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of recent recommendations for BioCardia and Appili Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
| Appili Therapeutics | 0 | 0 | 0 | 0 | N/A |
BioCardia presently has a consensus target price of $25.00, indicating a potential upside of 829.37%. Given BioCardia’s higher possible upside, equities analysts plainly believe BioCardia is more favorable than Appili Therapeutics.
Volatility & Risk
Institutional & Insider Ownership
20.6% of BioCardia shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Comparatively, 11.8% of Appili Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares BioCardia and Appili Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -278.27% |
| Appili Therapeutics | -450.64% | N/A | -186.27% |
Valuation & Earnings
This table compares BioCardia and Appili Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $428,000.00 | 11.45 | -$11.57 million | ($7.05) | -0.38 |
| Appili Therapeutics | $630,000.00 | 4.81 | -$2.80 million | ($0.03) | -0.83 |
Appili Therapeutics has higher revenue and earnings than BioCardia. Appili Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Summary
BioCardia beats Appili Therapeutics on 7 of the 12 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
